Compare Heron Therapeutics Inc (HRTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.67 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 2477.6× Heron Therapeutics Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| HRTX | VWO | |
|---|---|---|
Market Cap | $68.01M | $168.50B |
Volume | 1,891,941 | 9,650,999 |
Sector | Health | — |
52-Week High | $1.49 | $61.44 |
52-Week Low | $0.27 | $52.42 |
Typical Hold Time | 35 Days | 135 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
VWO trades at $59.67, down 0.3% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent news highlights institutional accumulation with Allianz and Alamar Capital increasing positions, though comparisons show developed market ETFs like VEA offer lower expense ratios and higher yields.
Outlook remains cautious with technical resistance at $60 and support at $59. Emerging markets face headwinds from China's weak retail and property sectors, though AI infrastructure spending offers partial offset. Investors should monitor dollar weakness as a potential catalyst for EM equities while weighing concentration risks in single-country exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
